1. Report Overview
1.1 Cell-Based Assays Overview
1.2 Cell-Based Assays Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research Methods and Analysis
1.8 Frequently Asked Questions
1.9 Associated Reports

Download Free Sample Pages of this report

2. Introduction to Cell-Based Assays and Applications
2.1 Cost of New Drug Discovery and Development Reaches $2.6bn – Companies Constantly Looking for Increased Efficiencies
2.2 Drug Discovery Approaches – Target-Based and Phenotype-Based Discovery
2.3 Drug Screening Assays
2.4 Animal Models Present In Vivo Conditions: But Do Results Translate to Humans?
2.5 Biochemical Assays and their Advantages over Animal Models
2.5.1 Applications of Biochemical Assays
2.5.2 Lead Identification and Toxicity Testing
2.6 Cell-Based Assays and their Advantages
2.7 2D vs 3D Cell-Based Assays
2.8 Advanced Cell-Based Assays
2.9 The Different Assay Detection Methods and Technologies
2.10 Cells used in Cell-Based Assays
2.10.1 Immortalised Cell Lines – Convenient but not Truly Representative of Normal Human Cell Lines
2.10.2 Primary Cells: Closer to the In Vivo Environment
2.10.3 Stem Cells: Potential to Overcome Limitations of Primary cells and Immortalised Cell Lines
2.11 Uses for Cell-Based Assays in Drug Discovery and Development
2.11.1 Target Validation
2.11.2 Primary Screening
2.11.3 Secondary Screening
2.11.4 ADME Screening
2.11.5 High Throughput Screening: Greatly Increases Efficiency

3. World Cell-Based Assays Market 2018-2028
3.1 Global Cell-Based Assays Market Forecast 2018-2028
3.2 Drivers for the Cell-Based Assays Market
3.2.1 Growing incidence of chronic diseases
3.2.2 Increasing R&D investment in drug discovery research
3.2.3 Growing adoption of high-throughput screening methodologies
3.2.4 Rapid technological advancements
3.3 Restraints for the Cell-Based Assays Market
3.3.1 High cost of instruments
3.3.2 Dearth of skilled professionals
3.4 Opportunities
3.4.1 Emerging countries to offer lucrative growth opportunities
3.4.2 Growing adoption of label-free cell-based assays
3.5 Trends
3.5.1 3D cell cultures
3.5.2 Microplate readers for cell-based assays
3.6 Cell-Based Assays Market by Products Type: Forecasts 2018-2028
3.6.1 Instrument Segment Forecasts 2018-2028
3.6.1.1 Equipment Needed to Conduct Cell-Based Assays
3.6.2 Consumables Forecasts 2018-2028
3.6.2.1 Reagents Forecasts 2018-2028
3.6.2.2 Assay kits Forecasts 2018-2028
3.6.2.3 Microplates Forecasts 2018-2028
3.6.2.4 Cell lines Forecasts 2018-2028
3.6.2.5 Probes and labels Forecasts 2018-2028
3.6.3 Software Forecasts 2018-2028
3.6.4 Services Forecasts 2018-2028
3.7 Cell-Based Assays Market by Application: Forecasts 2018-2028
3.7.1 Drug Discovery Forecasts 2018-2028
3.7.2 Basic Research Forecasts 2018-2028
3.7.3 Predictive Technology Forecasts 2018-2028
3.8 Cell-based Assays Market by End-User: Forecasts 2018-2028
3.8.1 Pharma & Biotech Companies Forecasts 2018-2028
3.8.2 Academic Institutions Forecasts 2018-2028
3.8.3 Contract Research Organizations (CROs) Forecasts 2018-2028

Download Free Sample Pages of this report

4. Leading National Markets for Cell-Based Assays, 2018-2028
4.1 Regional Breakdown of the Global Cell-Based Assays Market, 2018-2028
4.2 Global Cell-Based Assays market: Regional Forecast 2017-2028
4.3 The US Cell-Based Assays Revenue Forecast 2018-2028
4.4 European Union (EU) Cell-Based Assays Market 2018-2028
4.4.1 IMI’s Pan-European Drug Discovery Platform holds Much Promise
4.4.2 EU National Market Share Breakdown, 2017, 2023 and 2028
4.4.3 EU Market: Main National Forecasts, 2018-2028
4.4.4 German Cell-Based Assay Revenue Forecast, 2018-2028
4.4.5 French Cell-Based Assays Revenue Forecast, 2018-2028
4.4.6 UK Cell-Based Assays Revenue Forecast, 2018-2028
4.4.7 Spanish Cell-Based Assays Revenue Forecast, 2018-2028
4.4.8 Italian Cell-Based Assays Revenue Forecast, 2018-2028
4.5 Japanese Cell-Based Assays Revenue Forecast, 2018-2028
4.6 BRIC Nations (Brazil, Russia, India and China) Cell-Based Assays Market
4.6.1 BRIC Countries National Breakdown, 2017, 2023 and 2028
4.6.2 BRIC Countries National Forecasts, 2018-2028
4.6.3 Chinese Cell-Based assay Revenue Forecast, 2018-2028
4.6.4 Indian Cell-Based Assays Revenue Forecast, 2018-2028
4.6.5 Russian Cell-Based Assays Revenue Forecast, 2018-2028
4.6.6 Brazilian Cell-Based Assays Revenue Forecast, 2018-2028

5. Leading Companies in the Cell-Based Assays Market, 2017
5.1 DiscoverX Corporation (Eurofins)
5.1.1 Business Overview
5.1.2 Company Snapshot
5.1.3 DiscoverX: Cell-based Assay Product Portfolio
5.1.4 DiscoverX: Financial Overview
5.1.5 DiscoverX: Recent Developments
5.2 Thermo Fisher Scientific
5.2.1 Business Overview
5.2.2 Company Snapshot
5.2.3 Thermo Fisher Scientific: Cell-based Assay Product Portfolio
5.2.4 Thermo Fisher Scientific: Financial Overview
5.2.5 Thermo Fisher Scientific: Recent Developments
5.3 Cell Assay Innovations, Inc.
5.3.1 Business Overview
5.3.2 Company Snapshot
5.3.3 Cell Assay Innovations: Cell-based Assay Product Portfolio
5.3.4 Cell Assay Innovations: Recent Developments
5.4 InSphero AG
5.4.1 Business Overview
5.4.2 Company Snapshot
5.4.3 InSphero AG: Cell-based Assay Product Portfolio
5.4.4 InSphero AG: Recent Developments
5.5 QGel SA.
5.5.1 Business Overview
5.5.2 Company Snapshot
5.5.3 QGel SA.: Cell-based Assay Product Portfolio
5.5.4 QGel SA.: Recent Developments
5.6 Becton, Dickinson and Company
5.6.1 Business Overview
5.6.2 Company Snapshot
5.6.3 BD.: Cell-based Assay Product Portfolio
5.6.4 BD: Financial Overview
5.6.5 BD: Recent Developments
5.7 Promega Corporation
5.7.1 Business Overview
5.7.2 Company Snapshot
5.7.3 Promega: Cell-based Assay Product Portfolio
5.7.4 Promega Corporation: Recent Developments
5.8 BioVision, Inc.
5.8.1 Business Overview
5.8.2 Company Snapshot
5.8.3 BioVision, Inc.: Cell-based Assay Product Portfolio
5.8.4 BioVision, Inc.: Recent Developments
5.9 Marin Biologic Laboratories
5.9.1 Business Overview
5.9.2 Company Snapshot
5.9.3 Marin Biologic: Cell-based Assay Product Portfolio
5.10 Molecular Devices, LLC. (Danaher Corporation)
5.10.1 Business Overview
5.10.2 Company Snapshot
5.10.3 Molecular Devices, LLC: Cell-based Assay Product Portfolio
5.10.4 Danaher Corporation: Financial Overview
5.10.5 Molecular Devices, LLC.: Recent Developments
5.11 Porsolt
5.11.1 Business Overview
5.11.2 Company Snapshot
5.11.3 Porsolt: Cell-based Assay Product Portfolio
5.11.4 Porsolt: Recent Developments
5.12 CYTOO SA
5.12.1 Business Overview
5.12.2 Company Snapshot
5.12.3 CYTOO SA: Cell-based Assay Product Portfolio
5.12.4 CYTOO SA: Recent Developments
5.13 Pharmaceutical Product Development, LLC.
5.13.1 Business Overview
5.13.2 Company Snapshot
5.13.3 Pharmaceutical Product Development, LLC: Cell-based Assay Product Portfolio
5.13.4 Pharmaceutical Product Development, LLC.: Recent Developments
5.14 ProQinase GmbH
5.14.1 Business Overview
5.14.2 Company Snapshot
5.14.3 ProQinase GmbH: Cell-based Assay Product Portfolio
5.15 Charles River Laboratories International, Inc.
5.15.1 Business Overview
5.15.2 Company Snapshot
5.15.3 Charles River Laboratories International, Inc.: Cell-based Assay Product Portfolio
5.15.4 Charles River Laboratories International, Inc.: Financial Overview
5.15.5 Charles River Laboratories: Recent Developments
5.16 BioAgilytix Labs
5.16.1 Business Overview
5.16.2 Company Snapshot
5.16.3 BioAgilytix Labs: Cell-based Assay Product Portfolio
5.16.4 BioAgilytix Labs: Recent Developments
5.17 SGS Group
5.17.1 Business Overview
5.17.2 Company Snapshot
5.17.3 SGS Group: Cell-based Assay Product Portfolio
5.17.4 SGS Group, Inc.: Financial Overview
5.17.5 SGS Group: Recent Developments
5.18 Perkin Elmer Inc.
5.18.1 Business Overview
5.18.2 Company Snapshot
5.18.3 Perkin Elmer: Cell-based Assay Product Portfolio
5.18.4 Perkin Elmer: Financial Overview
5.18.5 Perkin Elmer: Recent Developments
5.19 General Electric Company (GE Healthcare)
5.19.1 Business Overview
5.19.2 Company Snapshot
5.19.3 General Electric Company.: Cell-based Assay Product Portfolio
5.19.4 General Electric Company: Financial Overview
5.19.5 General Electric Company: Recent Developments

Download Free Sample Pages of this report

6. Cell-Based Assays Technology, Trends and Future Outlook
6.1 Stem Cells: Vast Potential
6.1.1 The Benefits of Using Stem Cells in Cell-Based Assays
6.1.2 iPSCs: An Uncontroversial and Abundant Source
6.1.3 Companies Providing Stem Cell-Based Assays
6.2 Toxicity Testing: Important Field for Cell-Based Assays
6.3 3D Systems: The Advantages of Next Generation of Cell Systems
6.3.1 Complexity of 3D Systems is a Challenge but More are Reaching the Market
6.3.2 Organoids – The Future of Drug Development
6.3.2.1 Hurdles to the Future Organoid Market
6.3.2.2 Organoids Now and in the Future
6.3.3 Bio-Printing for Drug Development: Using 3D Printing Technology
6.4 Increasing Outsourcing of Cell-Based Assays
6.5 Label-Free Technology
6.6 GPCRs: A Common Drug and Drug Discovery Target
6.6.1 GPCRs in Cell-Based Assays
6.6.2 Allosteric GPCRs
6.7 Increasing Miniaturisation and Automation
6.7.1 Advantages of Miniaturisation
6.7.2 Advantages of Automation
6.8 Microfluids are Set to be a Trend
6.8.1 The Potential Challenges to Microfluids
6.9 Multiplexing: Improves Efficiency of cell-Based Assays
6.9.1 Advantages will Drive Growth
6.10 High Content Screening: A Well-Established Tool
6.10.1 The Future for HCS: Will Continue to Expand, Still Room for Innovation
6.11 Cell-Based Assays for the Development of Biologics

7. Qualitative Analysis of the Cell-Based Assays Market, 2017
7.1 SWOT Analysis of the Cell-Based Assays Market
7.1.1 Strengths Within the Cell-Based Assay Market
7.1.2 Weaknesses Within the Cell-Based Assays Market
7.1.3 Opportunities for the Cell-Based Assays Market
7.1.4 Threats to the Cell-Based Assays Market
7.2 STEP Analysis of the Cell-Based Assays Market
7.2.1 Social Factors
7.2.2 Technological Factors
7.2.3 Economic Factors
7.2.4 Political Factors

8. Conclusions from the Research and Analysis
8.1 Growth Has Been Driven by Advantages of Cell-Based Assays
8.2 Current Status of the Market and its Growth Drivers
8.3 The Most Dominant National Markets and Emerging Countries
8.4 Future Trends and Technology